Gallant HF

Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Gallant HF next to a phone displaying the phone app on top of a gradient background

Technology

Join Our Email List

Call to Order Products:
(800) 681-9293

Technology Overview

Optimize Patient Outcomes

Meet your heart failure (HF) patients' changing needs with our latest generation of CRT technology:

SyncAV™ Plus CRT technology offers dynamic AV timing to ensure electrical resynchronization.

22% fewer HF hospitalizations
for patients with SyncAV™ CRT technology enabled vs. patients with the technology disabled¹

100% of patients
had a narrower QRS²

MultiPoint™ pacing delivers multiple LV pacing pulses per cardiac cycle in both LV-only and biventricular pacing modes.

87% response rate
shown in the IDE study subgroup with anatomically programmed separation³

In a separate study, MultiPoint pacing led to significantly more responders and fewer non-responders vs. biventricular pacing (p <0.05)⁴

Faster, More Intuitive Programming

Gallant HF CRT-D solutions offer simple setup and customizable programming:

2X faster vector testing
13 vectors and 4 pacing electrodes provide more options and greater control

Gallant HF CRT-D Programming Guide

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog

Manuals & Technical Resources

Reimbursement & Coding

Customer Service

References

Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://www.escardio.org/Sub-specialty-communities/European-Heart-Rhythm-Association-(EHRA)/Research-and-Publications/EHRA-Essentials-4-You. Accessed May 15, 2020.
Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
Niazi, et al. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy—the multipoint pacing trial. JACC: Clinical Electrophysiology. Volume 3, Issue 13, 26 December 2017, Pages 1519-1522. https://doi.org/10.1016/j.jacep.2017.06.022. Accessed January 14, 2020.
Musaad AMA, Bokhari F, Sweidan R, et al. Long term effect of MultiPoint Pacing in Heart Failure patients on end systolic volume: preliminary results from a randomized and multicenter study in the Middle East. APHRS presentation, 2019.

MAT-2007532 v2.0

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0